Sympathetic Activity and Renal Denervation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

26 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary hypothesis:

Catheter-based renal denervation reduces central sympathetic activation in patients with refractory hypertension.

Secondary hypotheses:

1. The magnitude of the individual depressor response after catheter-based renal denervation depends on the extent of sympathoinhibition.
2. Both, the reduction in arterial pressure and in central sympathetic activation are sustained over time up to 24±3 months after catheter-based renal denervation.
3. Catheter-based renal denervation resets the sympathetic baroreflex to lower blood pressure values.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of Renal Denervation on Biological Variables

NCT01427049

Hypertension

COMPLETED

Renal Denervation in Treatment Resistant Hypertension

NCT01687725

Hypertension

COMPLETED

Effects of Electrical Baroreflex Stimulation on Sympathetic Activity, Renal Hemodynamics, and Insulin Sensitivity

NCT01355510

Hypertension

UNKNOWN

Renal Sympathetic Denervation in Mild Refractory Hypertension

NCT01656096

Refractory Hypertension

COMPLETED PHASE4

Renal Sympathetic Denervation as a New Treatment for Therapy Resistant Hypertension

NCT01850901

Hypertension Chronic Kidney Disease

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Refractory hypertension (as defined by the WHO: poorly controlled hypertension (\>140/90 mmHg) despite adequate doses of at least three antihypertensive drugs including a diuretic)
* Men or women aged \>18 years
* Intact peroneal nerve
* Written informed consent

Exclusion Criteria

* Diseases, dysfunctions, or medications (such as NET inhibitors) that exclude a participation in the study according to the investigator.
* Legal incompetence or circumstances that interfere with the patient´s ability to fully understand scope, relevance, and/or consequences of participation in this study.
* People in custody
* hypersensitivity to clonidine, phenylephrine, or nitroprusside-sodium
* sick sinus syndrome, second or third degree AV block, bradycardia \< 50 bpm (contraindication for clonidine)
* endogenous depression (contraindication for clonidine)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No